Loading...
XNAS
TCRT
Market cap8mUSD
Dec 05, Last price  
3.61USD
1D
0.56%
1Q
67.13%
Jan 2017
-32.52%
IPO
-77.44%
Name

Alaunos Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:TCRT chart
P/E
—
P/S
805.69
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-32.22%
Rev. gr., 5y
-49.08%
Revenues
10k
+100.00%
000000667,000800,000800,0001,373,0004,332,0006,861,0006,389,000146,00000398,0002,922,0005,00010,000
Net income
-5m
L-86.68%
-9,516,923-17,856,919-26,608,246-25,231,000-7,649,000-32,670,000-63,778,000-96,132,000-57,107,000-31,781,000-120,088,000-165,297,000-54,323,000-53,117,000-177,918,000-78,848,000-76,894,000-37,597,000-35,140,000-4,679,000
CFO
-5m
L-83.51%
-8,780,149-14,421,115-21,650,205-23,519,000-12,294,000-19,694,000-38,835,000-78,832,000-59,509,000-36,650,000-10,000-58,325,000-54,669,000-49,457,000-40,854,000-57,013,000-61,468,000-29,232,000-30,142,000-4,971,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
URL
https://alaunos.com/
IPO date
Aug 20, 2004
Employees
34
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT